Vaccine-based immunotherapy against atherosclerosis-relevant antigens, such as ApoB-derived peptides, has shown promise in preclinical models by expanding FoxP3+ regulatory T cells and IL-10-producing B cells [49, 127–131]. This evidence concerns the gene IL10 and atherosclerosis.